Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ayberk Bayramgil"'
Publikováno v:
Ulusal Romatoloji Dergisi, Vol 16, Iss 2, Pp 73-76 (2024)
Moyamoya disease is a rare chronic progressive cerebrovascular disease. The etiology of moyamoya disease has not been established yet. If an underlying cause is detected, moyamoya disease is called moyamoya syndrome. A 27-year-old right-handed male w
Externí odkaz:
https://doaj.org/article/578a11a5225749849d5ade654da375c3
Autor:
Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, Ahmet Bilici, Mesut Seker, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Ozgur Acikgoz, Irfan Cicin
Publikováno v:
Biomolecules & Biomedicine, Vol 23, Iss 6 (2023)
Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess t
Externí odkaz:
https://doaj.org/article/307cb5703f46446fb0e16815e2f38f8b
Autor:
Burcu Tunay, Omer Fatih Olmez, Ahmet Bilici, Ayberk Bayramgil, Gunes Dorukhan Cavusoglu, Huseyin Oz
Publikováno v:
Journal of Surgery and Medicine. 7:6-10
Background/Aim: Breast cancer is the second most common cause of cancer-related death in women worldwide. Predicting the prognosis in breast cancer with very high mortality is important in terms of disease treatment and increasing life expectancy. In
Autor:
Dokmetaş Hatice Sebile, Ayberk Bayramgil, Meric Dokmetaş, Fatih Kılıclı, Cavuşoğlu Guneş Dorukhan, Ku bra Karaipek, Yildirim Kizilkaya Ayşe Gul
Publikováno v:
Endocrine Abstracts.
Autor:
Dokmetaş Hatice Sebile, Ku bra Karaipek, Meric Dokmetaş, Fatih Kılıclı, Ayberk Bayramgil, Cavuşoğlu Guneş Dorukhan, Yaşar Ozdenkaya
Publikováno v:
Endocrine Abstracts.
Autor:
Dokmetaş Hatice Sebile, Meric Dokmetaş, Ayberk Bayramgil, Ku bra Karaipek, Cavuşoğlu Guneş Dorukhan, Cansu Temiz, Cem İdrisoğlu, Fatih Kılıclı, Ahmet Bilici
Publikováno v:
Endocrine Abstracts.
Autor:
Dokmetaş Hatice Sebile, Cavuşoğlu Guneş Dorukhan, Meric Dokmetaş, Fatih Kılıclı, Ayberk Bayramgil, Kubra Karaipek
Publikováno v:
Endocrine Abstracts.
Autor:
Omer Fatih Olmez, Burcu Tunay, Ahmet Bilici, Ayberk Bayramgil, Güneş Dorukhan Çavuşoğlu, Huseyin Oz
e13055 Background: We aimed to examine whether inflammatory markers and various risk scoring systems could be utilized to predict the prognosis of breast cancer patients hospitalized in the intensive care unit. Methods: In this retrospective cohort s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462b36860b3a60818ab4b5987a04f183
https://hdl.handle.net/20.500.12511/9922
https://hdl.handle.net/20.500.12511/9922
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(8)
Introduction Immune checkpoint inhibitors are drugs that are included in the guidelines of hematological and solid cancer treatments, give highly effective results and increase T cell functionality. However, these drugs can cause immune-related adver
Autor:
Sabin Göktaş Aydın, Ahmet Bilici, Ömer Fatih Ölmez, Cengiz Köksal, Ozgur Acikgoz, Jamshid Hamdard, Fethi Kilicaslan, Ayberk Bayramgil, Mehmet Seker, Ozcan Yildiz, Nur Buyukpinarbasili, Elkhan Mammadov
Publikováno v:
The breast journal. 27(1)
A 34-year-old woman had a history of breast cancer and underwent a right-sided nipple-sparing mastectomy and axillary dissection in 2014. She was staged as pT2N2aM0, IIIA, and the histopathological type was TNBC, grade 3. Ki-67 index was 35%-40%. The